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Dopamine (DA) transmission is deeply affected by drugs of abuse, and alterations in DA
function are involved in the various phases of drug addiction and potentially exploitable
therapeutically. In particular, basic studies have documented a reduction in the electrophys-
iological activity of DA neurons in alcohol, opiate, cannabinoid, and other drug-dependent
rats. Further, DA release in the Nucleus accumbens (Nacc) is decreased in virtually all
drug-dependent rodents. In parallel, these studies are supported by increments in intracra-
nial self stimulation (ICSS) thresholds during withdrawal from alcohol, nicotine, opiates,
and other drugs of abuse, thereby suggesting a hypofunction of the neural substrate of
ICSS. Accordingly, morphological evaluations fed into realistic computational analysis of the
medium spiny neuron of the Nacc, post-synaptic counterpart of DA terminals, show pro-
found changes in structure and function of the entire mesolimbic system. In line with these
ﬁndings, human imaging studies have shown a reduction of dopamine receptors accompa-
nied by a lesser release of endogenous DA in the ventral striatum of cocaine, heroin, and
alcohol-dependent subjects, thereby offering visual proof of the “dopamine-impoverished”
addicted human brain.The lasting reduction in physiological activity of the DA system leads
to the idea that an increment in its activity, to restore pre-drug levels, may yield signiﬁcant
clinical improvements (reduction of craving, relapse, and drug-seeking/taking). In theory,
it may be achieved pharmacologically and/or with novel interventions such as transcranial
magnetic stimulation (TMS). Its anatomo-physiological rationale as a possible therapeu-
tic aid in alcoholics and other addicts will be described and proposed as a theoretical
framework to be subjected to experimental testing in human addicts.
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Drug addiction is a brain disease that produces profound mod-
iﬁcations in human behavior (Hyman, 2007; Koob and Volkow,
2010), with important negative consequences at various levels,
including personal health, employment, family interactions, and
society in general (Chandler et al., 2009). Therapeutic possibilities
for this devastating illness are, with some rare exceptions, limited
to pharmacologic treatments that are largely unsatisfactory (Koob
et al., 2009; Leggio et al., 2010; Swift, 2010). Fromhere the necessity
to develop new therapeutic hypothesis/interventions independent
from those commonly employed.
Transcranial magnetic stimulation (TMS), through generation
of an electromagnetic ﬁeld capable of crossing painlessly through
the skull and inﬂuencing the underlying brain matter, appears to
be a promising candidate for treating addictive behaviors (Barr
et al., 2008; Feil and Zangen, 2010) and other brain diseases
(Kobayashi and Pascual-Leone, 2003). In brief, this relatively new
method allows modulation of discrete brain areas of the awake
and conscious subject under study. The pulsatile electromagnetic
ﬁeld generated around the coil crosses the skull and is capable
of directly exciting/inhibiting neurons in the underlying cortices
(Padberg and George, 2009). Commonly employed as a research
tool, TMS is recently afﬁrming its role as a potential therapeu-
tic means approved by the Food and Drug Administration for
brain pathologies such as drug-resistant major depression, bipo-
lar syndrome, and negative symptoms of schizophrenia. In the
drug addiction ﬁeld, the therapeutic potential of TMS has been
tested in nicotine-dependent subjects (Lang et al., 2008; Amiaz
et al., 2009), cocaine addicts (Boutros et al., 2001, 2005; Sun-
daresan et al., 2007; Politi et al., 2008), and alcoholics (Conte
et al., 2008; Mishra et al., 2010). Although the results are cer-
tainly encouraging, the disparity of clinical outcomes evaluated
in different studies and diversity of pattern/site/methodology of
stimulation precludes direct comparisons and hampers ﬁrm con-
clusions. However, in those studies in which craving was measured
(Politi et al., 2008; Amiaz et al., 2009; Mishra et al., 2010) sig-
niﬁcant reductions have been found, thus encouraging further
experimental scrutiny. At present, we are evaluating anti-craving
and alcohol-intake efﬁcacy of TMS in alcoholics (Addolorato
et al., in preparation), short and long-term cocaine intake in
treatment-seeking cocaine addicts (Pedetti et al., in preparation),
and money/cocaine choice in a lab study of cocaine addicts non-
seeking treatment (Martinez et al., in preparation). Nevertheless,
the brain site(s) to be stimulated/inhibited and the stimulation
parameters (i.e., frequency of stimulation, number of session etc.,)
are matters of intense debate and an appropriate rationale is
needed.
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DOPAMINE AS A POSSIBLE THERAPEUTIC TARGET
The role of central DA systems in the acute effects of drugs of abuse
was recognized long ago (Wise, 1980, 1987; Di Chiara and Imper-
ato, 1988). Even before (Ahlenius et al., 1973), attempts were made
to prevent human alcohol-induced euphoria through adminis-
tration of the DA synthesis inhibitor alpha methyl-para-tyrosine.
Although theoretically ineccepibile, this approach (reduction of
drug-induced DA increments to prevent abuse) is unlikely to have
a practical validity as any compound with DA antagonistic (i.e.,
neuroleptics) properties is known to be aversive in humans. On
the other hand, widely documented experimental evidence sug-
gests that the mesolimbic dopamine system is “hypofunctional”
in the addicted brain (Melis et al., 2005). In brief, the hypoth-
esis contends that decreased DA function in addicted subjects
results in a decreased interest to non-drug-related stimuli and
increased sensitivity to the drug of choice (Melis et al., 2005), lead-
ing to propose that restoring DA function might be therapeutically
advantageous.
Alcohol-dependent (in the present context the term “dependent,”
when referred to a non-human experimental subject, indicates a con-
dition in which the subject has shown unequivocally a proof of depen-
dency, i.e., somatic signs of withdrawal) rats show aprofound reduc-
tion of spontaneous ﬁring rate and burst ﬁring of antidromically
identiﬁed Nucleus accumbens (Nacc)-projecting ventral tegmen-
tal area (VTA) DA-containing neurons in rats (Diana et al., 1993)
and mice (Bailey et al., 2001) resulting in a concomitant reduc-
tion of microdialysate DA in the Nacc (Rossetti et al., 1992; Diana
et al., 1993; Barak et al., 2011). Further, the reduced dopaminergic
activity outlasts somatic signs of alcohol-withdrawal (Diana et al.,
1996, 2003) thereby suggesting a role for DA in the lasting conse-
quences of alcohol dependence while excluding the possibility of
a DA role in somatic aspects of withdrawal. Further, original (pre-
dependence) DA levels in the Nacc are restored when ethanol is
self (Weiss et al., 1996) and/or passively administered (Diana et al.,
1993, 1996). These observations are paralleled by intracranial self
stimulation (ICSS) studies showing that ethanol-withdrawn rats
are capable of maintaining the ICSS behavior provided that the
stimulus current intensity is increased (Schulteis et al., 1995). This
important observation strongly indicates that the neural substrate
responsible for maintaining the ICSS behavior is hyperpolarized,
or more refractory, in the alcohol-dependent subject as compared
with its control. Since the neural substrate of ICSS involves DA
axons (Yeomans, 1989; Yeomans et al., 1993) near the stimulating
electrode, the results are complementary to those reported above
and well support a deﬁcitary function of DA neurons. In addi-
tion, the perseverance of the reduction in DA activity (beyond
resolution of somatic signs of withdrawal) has also been docu-
mented in morphine-dependent rats (Diana et al., 1999), while a
dichotomy betweenDA function and somatic withdrawal has been
observed in cannabinoid–withdrawn rats (Diana et al., 1998). Sim-
ilarly, conditioned heroin withdrawal decreases reward sensitivity
(Kenny et al., 2006) which persists well beyond the initial phase
of withdrawal. These ﬁndings, observed across different addict-
ing compounds and experimental conditions, suggest that DA
hypofunction persists over time, although reverting to “normal-
ity”(Diana et al., 1999, 2006), eventually with species-speciﬁc time
course.
In addition to basic literature, reports in humans are also sup-
portive of a compromised role of DA transmission in alcoholics.
While alcohol increases DA release in healthy subjects (Boileau
et al., 2003) with some gender differences (Urban et al., 2010),
a reduced number of DA receptors has been observed (Volkow
et al., 1996; Martinez et al., 2005) in alcoholics that appears to be
accompanied by a blunted DA release (Martinez et al., 2005, 2007;
Volkow et al., 2007). While the reduced number of DA receptors
could be, at ﬁrst sight, be viewed as suggesting an increased DA
release, it should be noted that by administering the DA inhibitor
alpha methyl-para-tyrosine, Martinez et al. (2009) were able to
exclude this possibility. Indeed, while healthy controls do show
an increased raclopride binding after acute alpha methyl-para-
tyrosine administration, cocaine-dependent subjects do not (or to
a signiﬁcantly lesser extent; Martinez et al., 2009). Similar results
were obtainedwith the dopamine releasing agentmethylphenidate
(Volkow et al., 2007) and amphetamine (Martinez et al., 2005)
in alcoholics. Notably, artiﬁcially increasing the brain levels of
DAD2 receptors, using a replication-deﬁcient adenoviral vector
containing the rat cDNA insert for DAD2 into the Nacc, reduces
alcohol intake in spontaneously drinking rats, thereby offering
the counterproof that a potentiation of DA transmission may
have beneﬁcial effects on alcohol-seeking and alcohol-taking, in
experimental models (Thanos et al., 2001, 2004). In line with this
conclusion, a spontaneous high number of DA D2 receptors has
been shown to have a protective role in non-alcoholic members
of alcoholic families (Volkow et al., 2006). These ﬁndings fur-
ther support the notion that the number of DA receptors (and
consequently DA transmission) inversely correlates with alcohol
drinking.
These observations may suggest that “boosting” DA neurons
to produce more available DA in the synaptic cleft could allevi-
ate some of the symptoms of addiction and alcoholism, thereby
acquiring a therapeutic character. In theory, this could be achieved
by two different strategies: (1) DA-potentiating drugs and (2)
TMS. Both possibilities are discussed below.
DOPAMINE-POTENTIATING DRUGS
Although medications that increase DA activity could be effective
in treating alcohol abuse disorders, conﬂicting results have been
produced (Swift, 2010). For example, it was suggested that the DA
agonist bromocriptine reduced drinking in alcoholics (Lawford
et al., 1995), but a randomized, double-blind, placebo-controlled
study using a long-acting injectable bromocriptine preparation
in 366 alcoholic-dependent individuals did not ﬁnd difference in
alcohol relapse between medication and placebo (Naranjo et al.,
1997). Another example is the stimulant medication modaﬁnil
(DA indirect agonist), found to improve cognition in 40 alco-
holics with organic brain syndrome, but effects on drinking
could not be measured (Saletu et al., 1990). However, modaﬁnil
reduced cocaine use in a placebo-controlled studywith 62 cocaine-
dependent individuals (Dackis and O’Brien, 2005), while another
trial did not ﬁnd differences between modaﬁnil and placebo tested
for methamphetamine users (Shearer et al., 2010). While evidence
for the use of DA agonists as a treatment for alcohol and/or
substance use disorders is inconclusive (Swift, 2010), there has
been a revived interest for these drugs, possibly because adequate
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neurobiological rationale (Melis et al., 2005) is now available.
For example, aripiprazole (Semba et al., 1995; Burris et al., 2002;
Shapiro et al., 2003) a partial DA agonist which in principle should
antagonize DA when tone is high, whereas should increase DA
transmission when basic tone is low, represents a proposed treat-
ment for alcohol abuse disorders (Kenna et al., 2009). Human
laboratory alcohol studies have shown that aripiprazole reduces
drinking (Kranzler et al., 2008), especially in the more impulsive
alcoholic (Voronin et al., 2008). An fMRI study demonstrated that
aripiprazole signiﬁcantly attenuates neural activity in the ventral
striatum in response to alcohol cues (Myrick et al., 2010) thereby
suggesting a therapeutic potential for cue-induced relapse. Fur-
ther, a 12-week, double-blind, placebo-controlled treatment study
with 295 alcohol-dependent individuals found that aripiprazole
initially decreased heavy drinking days compared to placebo, but
this signiﬁcant effect was not presentwhen the target dose of 30 mg
was reached (Anton et al., 2008). This trial also showed greater
side-effects and greater study discontinuation in the aripiprazole
arm, as compared to placebo (Anton et al., 2008). Interestingly,
an open-label study of aripiprazole (Martinotti et al., 2009) and a
recent human laboratory study (Kenna et al., 2009) suggests that
lower doses of aripiprazole (5–15 mg per day) may be better toler-
ated and still reduce drinkingwith effects on relapse comparable to
those obtained with the opiate antagonist naltrexone (Martinotti
et al., 2009).
In summary,dopamine plays a key role in the addiction process,
but signiﬁcant side-effects have limited the use of medications that
work directly on the dopaminergic system. The use of DA partial
agonists with lower side effect proﬁles, and appropriate dosing
represent important directions for future research in this area.
TRANSCRANIAL MAGNETIC STIMULATION
Increasing DA tone with appropriate pharmacological tools, is
only one of the possible strategies. Endogenous activity of DA-
containing neurons can be augmented with non-pharmacological
tools such as TMS (Strafella et al., 2001) thereby providing, in
principle, an adjunct to the“therapeutic arsenal”against addiction,
endowed with lesser systemic side-effects and limited contraindi-
cations. However, while the rationale is “neurochemical” for phar-
macological agents (neurotransmitter receptors, brain area etc.,), it
must be anatomically based for TMS. Being that DA-containing
neurons are located deeply in the brainstem (thereby making the
neurons inaccessible to direct TMS stimuli) it becomes unavoid-
able to reach them indirectly through neurons located elsewhere
in the brain. The dorsolateral prefrontal cortex (DLPfcx) by pro-
jecting monosynaptically to the rat (Carr and Sesack, 2000) and
primate (Frankle et al., 2006) VTA may serve this function. These
studies show a projection from the PFC to midbrain DA neu-
rons, terminating both within the SN proper as well as in the
VTA. They arise from a broad region of the PFC, including the
DLPfcx, cingulate, and orbital cortices. Indeed, these pyramidal
neurons (Figure 1) could be exploited as the primary target of
the TMS stimulus and their increased activity to produce, ulti-
mately, an enhancement in DA availability in the synaptic cleft in
the Nacc. Schematically, the hypothesized circuit (Figure 2) would
be the following: TMS→DLPfcx→VTA→DA increase in fore-
brain projection site (i.e., Nacc). In this context, it is imperative
FIGURE 1 | Confocal reconstruction of Golgi-stained pyramidal
neurons from DLPfcx obtained by a projection of 55 scans for a depth
of 27.5μm in the z-axis. DLPfxc may represent a useful target for rTMS
stimulation.
FIGURE 2 |The scheme illustrates the proposed circuit to be activated
by theTMS stimulus (green) which, by activating the pyramidal
neuron (yellow) with its neurotransmitter glutamate, would excite: (1)
DA-containing neurons of theVTA (red) and (2) MSN of the Nacc (blue).
to employ stimulation parameters consonant with the physiolog-
ical activity of the system under study to restore pre-drug DA
levels. For instance, it has been shown that DLPfcx stimulation
produces bursts in rat DA neurons (Gariano and Groves, 1988;
Murase et al., 1993), highlighting the importance of stimulation
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parameters. Indeed, burst ﬁring is more efﬁcacious than single
spiking (of identical frequency but evenly spaced actionpotentials)
in inducing DA release in terminal areas (Gonon, 1988; Manley
et al., 1992). Consistently, the role of DLPfcx in regulating basal
DA activity through theVTA has been reported (Taber et al., 1995;
Karreman and Moghaddam, 1996).
Among the various factors that are likely to inﬂuence its efﬁ-
cacy, the importance of the baseline cortical activation state on
the impact of TMS is fundamental (Silvanto and Pascual-Leone,
2008). This state-dependency is key as the neural impact of any
external stimulus represents an interaction with the ongoing brain
activity at the time of stimulation. The effects of any external stim-
ulus are therefore not only determined by the properties of that
stimulus but also by the activation state of the brain. Accord-
ingly, it has been shown that baseline cortical activity determines
whether TMS hampers or hastens behavior (Silvanto et al., 2008).
The state-dependency principle described above would also apply
to the state of the DA system. The hypodopaminergic state (Melis
et al., 2005) should then “amplify” the effect of TMS as compared
with that expected in a normo-functioning DA system.
The responsivity of the neuron(s) to electrical and synap-
tic stimuli is strictly dependent on its morphological features,
which in turn, are deeply modiﬁed by drugs of abuse (Robin-
son and Kolb, 2004) and withdrawal from chronic treatment
with opiates (Sklair-Tavron et al., 1996; Spiga et al., 2003, 2005),
cannabis derivatives/analogs (Spiga et al., 2010), and psychostim-
ulants (Robinson and Kolb, 1997) have been shown to produce
reductions in DA cells size (Sklair-Tavron et al., 1996; Spiga et al.,
2003), paralleled by persistently (Diana et al., 2006) altered pat-
terns of synaptic connectivity, and spines density in the Nacc
and Pfcx (Robinson and Kolb, 1997). These architectural changes
would be expected to modify intrinsic spontaneous action poten-
tial generating capacity and responsiveness of the system to the
TMS stimuli. Accordingly, realistic computational analysis (Spiga
et al., 2010) of cannabis-dependent rats, generated by input of
experimentally veriﬁed morphometrical and electrophysiological
properties, predicts a lower action potential generation of Nacc
medium spiny neuron (MSN). These results suggest that MSN,
of cannabis-dependent rats are likewise hypofunctional. Consid-
ering that the main drive of these neurons is cortical glutamate
(Glu; see discussion in Spiga et al., 2010, and references therein;
Kalivas and Hu, 2006) it raises the possibility of a reduction of
Glu as a causal factor. This ﬁnding, thus offers the additional
possibility that stimulation of these units through TMS may be
advantageous in restoring pre-drug physiological activity. Indeed,
TMS cortical application should increase the activity of glutamate-
containing cortico-fugal ﬁbers monosynaptically impinging upon
the spine’s heads of NaccMSN(Groenewegen et al., 1991). Consid-
ering the fundamental role Glu plays in synaptic plasticity (Russo
et al., 2010), its role could also be exploited in LTP-like stimulation
parameters, ultimately aimed at producing lasting and enduring
restoration of original physiological activity. These characteris-
tics must be considered and coherently inserted into a framework
to obtain optimal stimulation parameters. In vivo recordings of
VTA-projecting DLPfcx neurons do ﬁre spontaneously around 4–
6 Hz (Pistis et al., 2001) and a TMS stimulus frequency of 10 Hz
could be a reasonable frequency to obtain a signiﬁcant increase
in VTA-projecting neurons aimed at stimulating the “deﬁcient”
dopamine system and its post-synaptic counterpart (i.e., MSN of
the Nacc).
Another factor to be considered is that all previous studies (see
above) applied the TMS stimulus monolaterally, yet obtaining a
reduction of alcohol craving (Mishra et al., 2010). While alco-
hol intake was not measured, and contralateral effects cannot be
excluded a priori, it is possible that application of TMS bilater-
ally, as in the case of the H-coil (Feil and Zangen, 2010), would
yield stronger cortical activation (larger number of ﬁbers acti-
vated) with an increased probability of a signiﬁcant increment of
bilateral DA release. It should be noted that unilateral TMS appli-
cation has already been reported to increase DA release (Strafella
et al., 2001) omolaterally in the human striatum, as well as in
rodents (Keck et al., 2002; Zangen and Hyodo, 2002), and even in
morphine-withdrawn rats (Erhardt et al., 2004), thereby support-
ing the rationale outlined above. Although Strafella et al. (2001)
proposed activation of (Glu-containing) cortico-fugal ﬁbers mak-
ing synaptic contact with DA-containing terminals in the ventral
striatum, to explain their results, it should be noted that the exis-
tence of axo-axonic contacts has always being questioned based
on the lack of appropriate anatomical observations (Groenewegen
et al., 1991; Meredith et al., 2008).
While many technical details for optimal stimulation parame-
ters need further investigation and optimization, the TMS appears
to deserve careful experimental scrutiny as a potential therapeu-
tic tool in alcoholics and other addicts. Indeed, with its nearly
absent systemic effects, minimal side-effects, and a low degree of
invasiveness, TMS may offer the ﬁrst opportunity for an efﬁca-
cious, non-pharmacological, therapeutic tool in alcoholism and
other chemical dependencies. If appropriately combined with a
solid neurobiological rationale (DA system), it may offer a unique
opportunity for developing further the ﬁrst “electrophysiological”
approach in studying and eventually treating the devastating and
widespread brain disease of addiction.
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